检索范围:
排序: 展示方式:
Adoptive cell transfer therapy for hepatocellular carcinoma
Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen
《医学前沿(英文)》 2019年 第13卷 第1期 页码 3-11 doi: 10.1007/s11684-019-0684-x
关键词: adoptive cell transfer therapy hepatocellular carcinoma T cell chimeric antigen receptor immunotherapy
《医学前沿(英文)》 2022年 第16卷 第3期 页码 322-338 doi: 10.1007/s11684-021-0901-2
关键词: cancer immunotherapy chimeric antigen receptor solid tumors tumor-associated antigen glycosylation O-glycans adoptive cell therapy
Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity
Chuanfeng Wu, Cynthia E. Dunbar
《医学前沿(英文)》 2011年 第5卷 第4期 页码 356-371 doi: 10.1007/s11684-011-0159-1
关键词: gene therapy hematopoietic stem cells insertional mutagenesis genotoxicity induced pluripotent stem cell
Challenges of NK cell-based immunotherapy in the new era
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 440-450 doi: tzg@ustc.edu.cn
Natural killer cells (NKs) have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization. Various cellular sources, including peripheral blood mononuclear cells (PBMCs), stem cells, and NK cell lines, have been used for producing NK cells. In particular, NK cells that expanded from allogeneic PBMCs exhibit better efficacy than those that did not. However, considering the safety, activities, and reliability of the cell products, researchers must develop an optimal protocol for producing NK cells from PBMCs in the manufacture setting and clinical therapeutic regimen. In this review, the challenges on NK cell-based therapeutic approaches and clinical outcomes are discussed.
关键词: natural killer cells immunotherapy adoptive transfer genetic modification immune checkpoint inhibitor
《医学前沿(英文)》 2022年 第16卷 第6期 页码 827-858 doi: 10.1007/s11684-022-0948-8
关键词: infertility stem cell therapy mesenchymal stem cells pluripotent stem cells
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
《医学前沿(英文)》 2009年 第3卷 第3期 页码 245-255 doi: 10.1007/s11684-009-0044-3
关键词: lung cancer carcinoma non-small cell lung cancer molecular markers targeted therapy
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
《医学前沿(英文)》 2020年 第14卷 第6期 页码 711-725 doi: 10.1007/s11684-020-0808-3
关键词: chimeric antigen receptor T (CAR-T) cell lymphoma cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity syndrome (ICANS)
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup
《医学前沿(英文)》 2022年 第16卷 第5期 页码 766-772 doi: 10.1007/s11684-021-0916-8
关键词: anlotinib chemotherapy short-term relapsed small-cell lung cancer
Chemical transdifferentiation: closer to regenerative medicine
null
《医学前沿(英文)》 2016年 第10卷 第2期 页码 152-165 doi: 10.1007/s11684-016-0445-z
Cell transdifferentiation, which directly switches one type of differentiated cells into another cell type, is more advantageous than cell reprogramming to generate pluripotent cells and differentiate them into functional cells. This process is crucial in regenerative medicine. However, the cell-converting strategies, which mainly depend on the virus-mediated expression of exogenous genes, have clinical safety concerns. Small molecules with compelling advantages are a potential alternative in manipulating cell fate conversion. In this review, we briefly retrospect the nature of cell transdifferentiation and summarize the current developments in the research of small molecules in promoting cell conversion. Particularly, we focus on the complete chemical compound-induced cell transdifferentiation, which is closer to the clinical translation in cell therapy. Despite these achievements, the mechanisms underpinning chemical transdifferentiation remain largely unknown. More importantly, identifying drugs that induce resident cell conversion in vivo to repair damaged tissue remains to be the end-goal in current regenerative medicine.
关键词: cell therapy cell transdifferentiation chemical compounds small molecules tissue regeneration
Precision medicine in acute lymphoblastic leukemia
Ching-Hon Pui
《医学前沿(英文)》 2020年 第14卷 第6期 页码 689-700 doi: 10.1007/s11684-020-0759-8
关键词: acute lymphoblastic leukemia molecular therapeutics targeted therapy tyrosine kinase inhibitors immunotherapy CAR T-cell therapy
Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)
《医学前沿(英文)》 2022年 第16卷 第5期 页码 815-826 doi: 10.1007/s11684-021-0891-0
关键词: B-cell lymphoma oral drug targeted therapy immunotherapy COVID-19 pandemic
The regulatory sciences for stem cell-based medicinal products
null
《医学前沿(英文)》 2014年 第8卷 第2期 页码 190-200 doi: 10.1007/s11684-014-0323-5
Over the past few years, several new achievements have been made from stem cell studies, many of which have moved up from preclinical stages to early, or from early to middle or late, stages thanks to relatively safe profile and preliminary evidence of effectiveness. Moreover, some stem cell-based products have been approved for marketing by different national regulatory authorities. However, many critical issues associated mainly with incomplete understanding of stem cell biology and the relevant risk factors, and lack of effective regulations still exist and need to be urgently addressed, especially in countries where establishment of appropriate regulatory system just commenced. More relevantly, the stem cell regulatory sciences need to be established or improved to more effectively evaluate quality, safety and efficacy of stem cell products, and for building up the appropriate regulatory framework. In this review, we summarize some new achievements in stem cell studies, especially the preclinical and clinical studies, the existing regulations, and the associated challenges, and we then propose some considerations for improving stem cell regulatory sciences with a goal of promoting the steadfast growth of the well-regulated stem cell therapies abreast of evolvement of stem cell sciences and technologies.
关键词: stem cell-based medicinal products (SCMPs) stem cell therapy (SCT) safety effectiveness standards guidelines regulatory science
Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang
《医学前沿(英文)》 2020年 第14卷 第6期 页码 811-815 doi: 10.1007/s11684-020-0740-6
关键词: anti-CD19 chimeric antigen receptor T cells mantle cell lymphoma relapsed or refractory long-term follow-up
NADPH oxidase and reactive oxygen species as signaling molecules in carcinogenesis
Gang WANG
《医学前沿(英文)》 2009年 第3卷 第1期 页码 1-7 doi: 10.1007/s11684-009-0018-5
关键词: free radicals tumor phox cell proliferation cancer therapy
《医学前沿(英文)》 2022年 第16卷 第5期 页码 784-798 doi: 10.1007/s11684-021-0911-0
关键词: uveal melanoma mutant GNAQ/11 palmitoylation BCL2 combination target therapy
标题 作者 时间 类型 操作
Adoptive cell transfer therapy for hepatocellular carcinoma
Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen
期刊论文
CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success?
期刊论文
Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity
Chuanfeng Wu, Cynthia E. Dunbar
期刊论文
Cell therapy for the treatment of reproductive diseases and infertility: an overview from the mechanism
期刊论文
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
期刊论文
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
期刊论文
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup
期刊论文
Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)
期刊论文
Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma
Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang
期刊论文